XLS Medical Appetite Reducer - Appetite Suppressant and Hunger Control for a more Efficient Weight Loss - 60 Capsules, 10 Days Treatment

Product Information

Responder rate for subjects who lost ≥3% and ≥5% of initial body weight at v6. LD = low dose; HD = high dose. a vs. placebo; b vs. placebo; c vs. low-dose group. Current solutions include Litramine, which was awarded the first Class II medical device certification for a plant-based weight management product in the world, and Tanitol, the first enzyme inhibitor that achieved medical device certification by targeting multiple digestive enzymes. Active Ingredient: Each capsule contains: Redusure™, a proprietary blend of high-swelling capacity dietary fibres. During the intervention period, no significant changes in fasting blood glucose and HbA1c levels were observed between the study groups. 67% of subjects in the IQP-AE-103 high-dose group had a reduction in triglyceride levels compared with 37% in the placebo group ( ). Changes in total/low-density lipoprotein (LDL)/high-density lipoprotein (HDL) cholesterol were not significant at the end of the study, but a post hoc subgroup analysis performed with subjects with baseline total cholesterol level above 6.2 mmol/L revealed pre-post reductions in total cholesterol of 1.22 ± 1.10 mmol/L ( ), 0.58 ± 0.90 mmol/L ( ), 0.13 ± 0.31 mmol/L ( ), and reductions in LDL cholesterol of 1.18 ± 1.06 mmol/L ( ), 0.49 ± 0.74 mmol/L ( ), and 0.23 ± 0.29 mmol/L ( ), in high-dose, low-dose IQP-AE-103, and placebo groups, respectively. Flattened and prolonged glucose response after every meal: Avoid unexpected spikes in blood glucose levels with this natural blend of dietary fibres

National Institute for Health and Care Excellence, Weight Management: Lifestyle Services for Overweight or Obese Results. Public Health Guideline, National Institute for Health and Care Excellence, London, UK, May 2014. Clinical data on plant-based oral solutions show non-invasive weight management can be effective and sustainable Institute of Medicine, Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients), The National Acadamy Press, Washington, DC, USA, 2005.Figure 3: Tanitol 14-week placebo-controlled, randomised, double-blind clinical trial results Weight loss through increased satiety Our study has several limitations. One limitation is that it was performed over a short period of only 12 weeks, with no follow-up conducted after the study was finished and no weight maintenance phase after the initial weight loss. As such, the study provides no information about the effects of IQP-AE-103 on long-term weight maintenance and on other obesity-related conditions such as diabetes or cardiovascular disease. In addition, the study included subjects of a wide age range. Although the distribution of different age groups was not substantially different between groups in the current study, it may be helpful to include age as a stratification factor in future study. Changes in gut microbiota composition occur with age [ 52], and it has been shown that altered gut microbiota may be associated with obesity [ 53], since IQP-AE-103 contains fibres and polysaccharides from okra pod and inulin, it is likely that the composition of the intestinal gut microbiota may be positively influenced by the consumption of IQP-AE-103. Hence, analysis of gut microbiota changes in overweight and obese subjects of different age groups may provide additional knowledge regarding the effect of IQP-AE-103. Moreover, appetite sensations in the study were assessed using VAS and rating scales, which were not validated for the specific use to measure changes in a similar study design. Last but not least, self-reporting of dietary intake by study subjects, applied for reasons of practicality, may be a limitation. It is known that factors such as gender and weight status affect subjects’ behavior in reporting energy intake; for example, females tended to underreport compared with males, and increasing weight status was associated with an increase in underreporting of energy intake [ 54]. As such, results obtained in the current study, primarily evaluating weight loss, on IQP-AE-103’s effect on appetite sensations remain exploratory. To evaluate a potential effect of IQP-AE-103 on food/energy intake, quantification of actual calorie intake by recording food consumption at an “ad libitum” lunch may be considered in future studies.

Weight management treatments range from natural, oral solutions to risky, invasive surgical procedures. In the dietary supplement industry, new products constantly offer promises to dieters; yet, most are born from similar technology and mechanisms of action. The primary endpoint of this study was the comparison of the mean body weight (kg) change between IQP-AE-103 high dose and placebo after 12 weeks of intervention from baseline, in overweight and moderately obese subjects. The evaluation of the efficacy of IQP-AE-103 was based on the null hypothesis that there are no statistical differences between IQP-AE-103 and placebo in mean reduction of body weight after 12 weeks of treatment. The nonparametric Mann–Whitney U test for independent samples was applied. The testing was carried out by the determination of the rank sum of individual body weight changes.As food exits the stomach more slowly, the complex may delay the intestine’s absorption of glucose, helping to reduce the appetite and sustain feelings of satiety. Based on the physicochemical properties of okra pods and inulin, and the fat binding capacity shown in vitro, it was hypothesized that a product containing powdered okra pods and inulin could potentially contribute to weight loss. Hence, the primary objective of this randomised, double-blind, placebo-controlled clinical study was to evaluate the weight loss potential of IQP-AE-103 over the period of 12 weeks in overweight and moderately obese subjects. In this study, it was demonstrated that in conjunction with a hypocaloric diet, IQP-AE-103 at both low dose (990 mg okra and 255 mg inulin/day) and high dose (1980 mg okra and 510 mg inulin/day) causes significant weight loss and that the effects are greater than those in the placebo. Baseline body weight was reduced by 5.03 ± 2.50 kg in the high-dose group and by 3.01 ± 2.19 kg in the low-dose group, compared with 0.98 ± 2.06 kg in the placebo group. Also, for the high-dose group, weight loss effect due to IQP-AE-103 consumption was observed as early as at 2 weeks of treatment and was sustained over the course of the 12-week intake period. More importantly, the proportion of subjects who lost at least 5% of baseline body weight was 60.0% in the high-dose IQP-AE-103 group, a proportion that is significantly higher than that in the low-dose and the placebo groups. Such weight loss due to the intake of IQP-AE-103 is considered to be of clinical relevance as European Medicines Agency associates a weight loss of 5% or more with a decrease of disease risk factors associated with overweight and obesity [ 38]. Subgroup analysis showed that although both IQP-AE-103 high- and low-dose consumptions led to significant weight loss in overweight subjects, for moderately obese subjects, only high dose caused a significant body weight reduction. Subgroup analysis also showed a statistically significant weight loss in both high- and low-dose IQP-AE-103 groups in subjects aged 41–65 years when compared with placebo group, whereas only the high-dose group showed a significant weight loss versus placebo in subjects aged 18–40 years. Clinically proven efficacy: Promote weight loss through a reduced food consumption - prevent unnecessary snaking and hunger pangs Hunger Buddy by XLS is a medical device. Only recommended for adults over 18 years of age. The use of this product by adolescents 12-18 years old is subject to the supervision of healthcare professionals. This product must be taken as a whole capsule with a full glass of water (approximately 250 ml). Do not open the capsule and avoid taking in powder form to avoid choking. Please read the enclosed product insert before use. It is recommended to drink at least 2 litres of water a day. Slight constipation could occur in case of limited liquid intake. Do not take during pregnancy or whilst breastfeeding, or if your BMI is below 18.5. Consult your healthcare professional before taking this product if you have any medical condition or if you are diabetic. Keep out of reach and sight of children. Please read the enclosed product insert before use. Product Specification

InQpharm’s Redusure is a patent-pending fibre complex based on glucomannan, carrageenan and xanthan gum. Designed to work like an impermanent, natural lap band, Redusure swells in the stomach, filling up to 43% of the volume, helping individuals to feel fuller for longer. For the treatment and prevention of excess weight. Fight food cravings & cut portion sizes. 94% experinced a feeling of fullness. Please note that not all products available online are available in the stores. The RRP against which any savings comparisons we make to the listed sale Proprietary ingredient clinically shown to increase satiety and support significant weight loss in overweight and obese adults All other efficacy as well as the safety and concurrent variables were exploratively examined and were descriptively assessed. For the metric data (continuous data), the statistical characteristics were given (number, mean, standard deviation, median, extremes, quartiles, and 95% confidence interval of mean). For ordinal data (discrete data), frequency distribution was performed. All nominal data (categorical data) were summarized using frequency tables. All variables were evaluated primarily by exact nonparametric procedures: (i) Kruskal–Wallis test for more than two independent groups (comparison of groups or subgroups) (ii) Mann–Whitney U test for independent groups (comparison of groups or subgroups) (iii) Wilcoxon test for dependent groups (comparison of pre-post within groups or subgroups) (iv) Fisher’s exact test for comparison of percentage.

We understand that not everyone can donate right now, but if you can afford to contribute. Your contributions help us rent servers, add new features, and preservation projects. IQP-AE-103 demonstrated a very good tolerability profile in our study as expected since okra is typically consumed as food and inulin is widely consumed as fibre/prebiotic supplements. Additionally, okra has shown no toxicity in animals at doses up to 4000 mg/kg [ 50]. A safety review on inulin by Carabin and Flamm [ 51] has found no treatment-related toxic effects nor carcinogenicity or genotoxicity. In our study, the overall tolerability towards the IQP-AE-103 in high and low doses was comparable to that in the placebo, according to the rating by the subjects and the investigator. Observed adverse events were unrelated with the IQP-AE-103 consumption. Moreover, there were no significant differences in stool frequency. Therefore, in contrast to many available anti-obesity products that cause unpleasant and sometimes serious side effects, IQP-AE-103 could be considered as a safe, well-tolerated, and effective weight management agent.

XLS-Medical Appetite Reducer is a medical device. Only recommended for adults over 18 years of age. The use of this product by adolescents 12-18 years old is subject to the supervision of healthcare professionals. This product must be taken as a whole capsule with a full glass of water (approximately 250 ml). Do not open the capsule and avoid taking in powder form to avoid choking. Please read the enclosed product insert before use. It is recommended to drink at least 2 litres of water a day. Slight constipation could occur in case of limited liquid intake. Do not take during pregnancy or whilst breastfeeding, or if your BMI is below 18.5. Consult your healthcare professional before taking this product if you have any medical condition or if you are diabetic. Keep out of reach and sight of children. Product SpecificationThis research confirms Redusure's role in appetite reduction by promoting pleasant feelings of fullness when taken before meals,' stated Holly Tully, VP of Marketing, InQpharm NA. 'The study also reveals just how effective these appetite-reducing properties are in helping individuals lose weight at a consistent, healthy rate.' No significant differences in changes of feeling of fullness and food cravings between the study arms were observed. However, feeling of hunger decreased in 66% of subjects in the high-dose group (statistically significant pre-post change). This may be related to the swelling property of okra pods reported earlier [ 22]. Okra constituents such as soluble fibre or polysaccharides may increase viscosity of taken meal and form a gel, thus increasing gastric distension and thereby promoting satiety [ 45]. The mean reduction in waist circumference was more pronounced in both IQP-AE-103 groups, compared with that in the placebo group at the end of the study. Subjects in the high-dose IQP-AE-103 arm had a mean reduction in waist circumference of 4.1 ± 3.3 cm, whereas the mean reduction in the low-dose IQP-AE-103 arm was 2.5 ± 2.4 cm, in contrast to only 0.9 ± 1.6 cm reported in the placebo group ( and versus placebo, respectively). Also, there were statistically significant differences in the percentage of subjects with reduction in hip circumference between the study groups at week 12, between high-dose IQP-AE-103 and the placebo group (91.4% vs. 54.8%; ), as well as between low-dose IQP-AE-103 and placebo groups (80% vs. 54.8%; ), however, not between low- and high-dose IQP-AE-103 groups ( ). No statistically significant differences in waist-to-hip ratio between the study groups were reported at week 12. Blood lipid parameters, fasted glucose, and hemoglobin A1c (HbA1c) were assessed at visit 1 and visit 6. In summary, the study results provide the first promising evidence that the intake of IQP-AE-103 causes weight loss in overweight and moderately obese subjects in conjunction with a mild hypocaloric diet. The 12-week treatment with IQP-AE-103 also showed very good tolerability. Taken together, IQP-AE-103 can be considered as a safe and effective strategy in fighting obesity with potential benefits in maintaining healthy blood lipids. Data Availability